Michelle Johnson, M.B.A.

Chief Executive Officer

Michelle has over 20 years experience in strategy, operations, marketing, and business management, covering multiple industries. As CEO of MetrumRG, Michelle is responsible for providing strategic leadership, management, and direction to ensure the company is fulfilling its mission and goals. Michelle holds an MBA from Babson College, with a concentration in business analytics, and a Bachelor of Arts degree in advertising and public relations from the University of Central Florida.

Recent publications by this scientist

Cost Effectiveness of Individualized Dosing for Hypothetical New Drug in Atopic Dermatitis: A Pharmacometric-Pharmacoeconomic Simulation Study

May 27, 2025

A companion poster to the ASCPT print copy, this visual presentation emphasizes the simulation approach used to evaluate individualized dosing strategies and their economic implications. Results underscore the importance of reducing discontinuation rates to enhance value.

Download PDF

Pharmacometric-Pharmacoeconomic Modeling and Simulation to Assess Target Product Profile Characteristics in Early Drug Development: Application to Atopic Dermatitis

May 27, 2025

This poster presents a modeling framework linking target product profile characteristics to cost-effectiveness outcomes in early drug development for atopic dermatitis. It highlights how persistence of therapy, more than efficacy metrics, may improve cost utility of new treatments.

Download PDF

Individualized dosing may improve the cost effectiveness of new therapeutics in atopic dermatitis

May 27, 2025

This study uses pharmacometric and pharmacoeconomic modeling to explore the cost effectiveness of individualized dosing for a hypothetical new atopic dermatitis drug compared to dupilumab. Simulation scenarios tested the impact of treatment discontinuation rates, efficacy variability, and pricing on cost utility outcomes.

Download PDF